BECTON DICKINSON AND CO (BDX)

US0758871091 - Common Stock

236.3  -0.32 (-0.14%)

After market: 236.3 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BECTON DICKINSON AND CO

NYSE:BDX (5/17/2024, 7:04:00 PM)

After market: 236.3 0 (0%)

236.3

-0.32 (-0.14%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap68.27B
Shares
PE19.32
Fwd PE16.31
Dividend Yield1.62%
Analysts
IPO
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BDX Daily chart

Company Profile

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. The company is headquartered in Franklin Lakes, New Jersey and currently employs 73,000 full-time employees. The firm is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The firm's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The firm's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The firm's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Company Info

BECTON DICKINSON AND CO

One Becton Drive

Franklin Lakes NEW JERSEY 07417

P: 12018476800

CEO: Thomas E. Polen

Employees: 73000

Website: https://www.bd.com/

BDX News

News Image3 days ago - BD (Becton, Dickinson and Company)Women in U.S. Can Now Collect Their Own Sample for Cervical Cancer Screening

/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration...

News Image9 days ago - Market News VideoSee Which Of The Latest 13F Filers Holds Becton, Dickinson & Co
News Image15 days ago - BusinessInsiderBecton & Dickinson 'Is Well On Its Way To Achieving 2025 Commitments,' Analyst Optimistic On Outlook

BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance was raised for 2024 sales, and EPS was adjusted. William Blair rates BDX shares Outperform.

News Image16 days ago - ChartmillIn today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Thursday's session.

Unusual volume S&P500 stocks in Thursday's session

News Image16 days ago - InvestorPlaceBDX Stock Earnings: Becton, Dickinson Beats EPS, Beats Revenue for Q2 2024

BDX stock results show that Becton, Dickinson beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

News Image16 days ago - BD (Becton, Dickinson and Company)BD Reports Second Quarter Fiscal 2024 Financial Results

Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7%...

BDX Twits

Here you can normally see the latest stock twits on BDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example